Virax Biolabs Stock Doubles on Southeast Asia Supply Deal with Fosun Diagnostics

Shares of Virax Biolabs Group Limited (NASDAQ:VRAX) soared 100% on Thursday after the company secured an exclusive commercial supply agreement with Fosun Diagnostics. The deal covers the distribution of Virax's ImmuneSelect immune profiling products in six key Southeast Asian markets.

Details of the Agreement

The multi-country agreement grants Fosun Diagnostics exclusive rights to supply Virax's products in Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. Under the terms, Virax will immediately begin supplying its ImmuneSelect products, including ELISpot assay plates used to measure cellular immune responses, to Fosun under purchase orders.

This framework is designed to generate near-term revenue and support Virax's commercial expansion in the region. The pricing structure includes volume-based tiers, reflecting scalable economics across the ASEAN markets. The agreement also provides a pathway for expansion into additional products, larger supply arrangements, and potential OEM or private-label opportunities, though exclusivity is contingent on meeting minimum purchase and performance requirements.

Strategic Focus and Market Entry

Ad

The initial commercial focus will be on tuberculosis-related research applications in Thailand. According to the announcement, Fosun has already identified customer demand through the regional network of its parent company, Fosun Pharma. A successful rollout in Thailand could precede expansion into the other five countries covered by the deal.

It is important for investors to note that ImmuneSelect is a commercially available product line intended for research-use-only. This is distinct from ViraxImmune, the company's separate diagnostic platform that is currently undergoing clinical and regulatory development.

Context and Market Impact

The partnership provides Virax with a powerful distribution channel in Asia. Fosun Diagnostics is the core diagnostics entity of Fosun Medtech, a division of Fosun Pharma, which reported revenues of approximately $5.8 billion in 2025. The significant market reaction underscores investor optimism about the deal's potential to accelerate Virax's revenue generation and establish a strong foothold in the Asian life sciences market.